Disclaimer: The views and opinions expressed in this material are those of the healthcare professional and do not necessarily represent the views of Novartis.

 

Molecular MRD monitoring and its role in AML 
Konstanze Dohner 

Prof Dohner provides her expertise from Germany to examine the prognositic impact of measurable residual disease (MRD) in AML. This presentation also analyses the outcomes of MRD monitoring by next generation sequencing (NGS). 
Download slides

 

AU-12630
×

Medical Information Request

×

Ask Speakers